{"doi":"10.1016/j.ekir.2022.07.175","title":"Corrigendum to PHASE 2 STUDY TO EVALUATE EFFICACY AND SAFETY OF PEGCETACOPLAN IN THE TREATMENT OF PATIENTS WITH POSTTRANSPLANT RECURRENCE OF C3G OR IC MPGN","abstract":"The authors regret that N. Palakow was incorrectly listed as an author for this abstract. She should be removed from the author slate. The authors would like to apologise for any inconvenience caused. DOI of original article: 10.1016/j.ekir.2022.04.069 POS-047 PHASE 2 STUDY TO EVALUATE EFFICACY AND SAFETY OF PEGCETACOPLAN IN THE TREATMENT OF PATIENTS WITH POSTTRANSPLANT RECURRENCE OF C3G OR IC MPGNKidney International ReportsVol. 7Issue 6PreviewComplement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN) are rare but devastating kidney diseases. There are no approved therapies for these diseases, and 50% of patients develop recurrence of disease and graft loss after transplant. Uncontrolled complement activation at the level of C3 leads to excessive production of C3 breakdown products and deposition in the kidney. As an investigational C3 and C3b inhibitor, pegcetacoplan has the potential to address the underlying pathophysiology of C3G and IC-MPGN. Full-Text PDF Open Access","journal":"Kidney International Reports","year":2022,"id":311910,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9603,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":908872,"name":"Bradley P. Dixon","orcid":"0000-0003-3704-0922","position":1,"is_corresponding":false},{"id":1008874,"name":"P. Walker","orcid":null,"position":2,"is_corresponding":false},{"id":1008875,"name":"F. Fakhowri","orcid":null,"position":3,"is_corresponding":false},{"id":1008876,"name":"I. Soomro","orcid":null,"position":4,"is_corresponding":false},{"id":1008877,"name":"T. Cook","orcid":null,"position":5,"is_corresponding":false},{"id":5493,"name":"Z. Zhang","orcid":"0000-0002-7853-9079","position":6,"is_corresponding":false},{"id":1008355,"name":"Zain Ahmad","orcid":"0009-0003-3618-7102","position":7,"is_corresponding":false},{"id":1008878,"name":"H. Kocinsky","orcid":null,"position":8,"is_corresponding":false},{"id":1008873,"name":"Marcus Jerome Pickering","orcid":null,"position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T00:33:32.327694Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}